Component

Chromium(III) phenylalaninate complex

Chromium(III) phenylalaninate complex. Species, exposure and limitations are retained in each linked claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

  1. Rapid urinary loss accounted for much newly absorbed chromium picolinate; in the human comparison, seven-day retention was similarly low for picolinate and phenylalaninate.

    Chromium(III) picolinate / CrPic → Urinary chromium excretion source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/chromium-research/22814636.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6", "start_char": 0, "end_char": 1673, "text_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6"}
    experimental_model
    Radiolabeled-compound whole-body counting in rats and a human volunteer
    exposure
    Oral 51Cr-labeled supplement complexes; human intraindividual comparison of picolinate and phenylalaninate
    limitations
    Human component was a volunteer comparison, not a large population trial. Apparent absorption, absorbed amount before early urinary loss and seven-day retention are different quantities.
    nutrient_topic
    Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium
    organism
    Rat and human; species-specific results retained
    plain_language
    A compound can enter the body more readily yet leave quickly, without increasing retained chromium.
    primary_references
    [chromium-p22814636] Bioavailability of chromium(III)-supplements in rats and humans. (2012). https://pubmed.ncbi.nlm.nih.gov/22814636/ DOI: 10.1007/s10534-012-9571-5
    tissue_or_cell_type
    Intestinal uptake, urine and whole-body retention

    Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 120–131

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Radiolabeled-compound whole-body counting in rats and a human volunteer · source_derived_draft · unverified_draft

    ### chromium-picolinate-absorption-retention Rapid urinary loss accounted for much newly absorbed chromium picolinate; in the human comparison, seven-day retention was similarly low for picolinate and phenylalaninate. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A compound can enter the body more readily yet leave quickly, without increasing retained chromium. organism: Rat and human; species-specific results retained tissue_or_cell_type: Intestinal uptake, urine and whole-body retention experimental_model: Radiolabeled-compound whole-body counting in rats and a human volunteer limitations: Human component was a volunteer comparison, not a large population trial. Apparent absorption, absorbed amount before early urinary loss and seven-day retention are different quantities. exposure: Oral 51Cr-labeled supplement complexes; human intraindividual comparison of picolinate and phenylalaninate evidence_span: {"source_cache": "artifacts/chromium-research/22814636.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6", "start_char": 0, "end_char": 1673, "text_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6"} [chromium-p22814636] Bioavailability of chromium(III)-supplements in rats and humans. (2012). https://pubmed.ncbi.nlm.nih.gov/22814636/ DOI: 10.1007/s10534-012-9571-5
    Complete structured claim and evidence

  2. Apparent absorption in the human comparison was about 0.8–1%, higher than the 0.04–0.24% range across the tested rat complexes.

    Chromium(III) picolinate / CrPic → Intestinal chromium uptake source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/chromium-research/22814636.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6", "start_char": 0, "end_char": 1673, "text_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6"}
    experimental_model
    Radiolabeled-compound whole-body counting in rats and a human volunteer
    exposure
    Oral 51Cr-labeled supplement complexes; human intraindividual comparison of picolinate and phenylalaninate
    limitations
    Human component was a volunteer comparison, not a large population trial. Apparent absorption, absorbed amount before early urinary loss and seven-day retention are different quantities.
    nutrient_topic
    Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium
    organism
    Rat and human; species-specific results retained
    plain_language
    Absorption differed between humans and rats; the rat percentage should not be assigned directly to people.
    primary_references
    [chromium-p22814636] Bioavailability of chromium(III)-supplements in rats and humans. (2012). https://pubmed.ncbi.nlm.nih.gov/22814636/ DOI: 10.1007/s10534-012-9571-5
    tissue_or_cell_type
    Intestinal uptake, urine and whole-body retention

    Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 133–144

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Radiolabeled-compound whole-body counting in rats and a human volunteer · source_derived_draft · unverified_draft

    ### chromium-species-bioavailability Apparent absorption in the human comparison was about 0.8–1%, higher than the 0.04–0.24% range across the tested rat complexes. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: Absorption differed between humans and rats; the rat percentage should not be assigned directly to people. organism: Rat and human; species-specific results retained tissue_or_cell_type: Intestinal uptake, urine and whole-body retention experimental_model: Radiolabeled-compound whole-body counting in rats and a human volunteer limitations: Human component was a volunteer comparison, not a large population trial. Apparent absorption, absorbed amount before early urinary loss and seven-day retention are different quantities. exposure: Oral 51Cr-labeled supplement complexes; human intraindividual comparison of picolinate and phenylalaninate evidence_span: {"source_cache": "artifacts/chromium-research/22814636.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6", "start_char": 0, "end_char": 1673, "text_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6"} [chromium-p22814636] Bioavailability of chromium(III)-supplements in rats and humans. (2012). https://pubmed.ncbi.nlm.nih.gov/22814636/ DOI: 10.1007/s10534-012-9571-5
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards